Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Clover Health Investments, Corp.

RADNOR, PA / ACCESSWIRE / February 27, 2021 / Kessler Topaz Meltzer & Check, LLP’s law firm recalls that Clover Health Investments, Corp. (NASDAQ: CLOV) (“Clover”) on behalf of those who have publicly purchased or acquired Clover, a class action lawsuit for securities fraud was filed between October 6, 2020 and February 4, 2021 (including the “Class Period”) and securities / or Clover securities purchased or acquired in accordance with Clover’s registration statement and prospectus issued in connection with the merger in December 2020, or traceable.

Important Deadline Reminder: Investors who have purchased or acquired publicly traded Clover Securities during the Class Period may apply for appointment as Plaintiff’s Principal Representative no later than April 6, 2021. For more information or to learn how to participate in this litigation, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435); toll free at (844) 887-9500; by email atinfo@ktmc.com; or click on https://www.ktmc.com/clover-health-investments-corp-securities-class-action?utm_source=PR&utm_medium=link&utm_campaign=clover

According to the complaint, Clover offers health insurance benefits. Clover was floated on the stock exchange through a reverse merger with IPOC, a Special Purpose Acquisition Company (the “Business Combination”). Prior to the business combination, IPOC was listed on the New York Stock Exchange. The class period begins on October 6, 2020 when Clover issued a press release announcing its intention to become a public company through a merger with IPOC. On October 20, 2020, Clover filed its registration statement and preliminary proxy statement / prospectus on a Form S-4 with the SEC (the “Registration Statement”). The registration declaration was changed on December 9, 2020 and December 10, 2020 and declared effective on December 11, 2020. The registration statement touted Clover’s growth as strong and organic.

The story goes on

On February 4, 2021, ahead of market hours, Hindenburg Research released a research report showing that Clover’s flagship platform, Clover Assistant, is the subject of an investigation by the US Department of Justice (“DOJ”) on various topics, including illegal setbacks , war, marketing practices and undisclosed related party transactions. Hindenburg noted that Clover’s revenue growth was not based on technology, but rather on deceptive sales practices. Following this news, Clover Common Stock (CLOV) fell $ 1.72 per share, or 12.3%, to $ 12.23 per share on February 4, 2021, and Clover Warrants (CLOVW) fell $ 0.18 per warrant or 5% to $ 3.39 per warrant on February 4, 2021.

On February 5, 2021, before the market opened, Clover filed a Form 8-K stating that the SEC was “investigating and requesting the retention of documents and data in.” Regarding Certain Matters “performed which is referred to in the [Hindenburg Research report]”Following this news, Clover Common Stocks (CLOV) fell $ 0.53 per share, or 4.3% during intraday trading, and Clover Warrants (CLOVW) fell $ 0.28 per share on February 5, 2021 Warrant or 8.2% during intraday trading on February 5. 2021.

The complaint alleges that throughout the classroom, the defendants made false and / or misleading statements and / or failed to disclose that: (1) Clover from the DOJ on at least 12 questions ranging from illegal kickbacks to marketing practices; actively investigated undisclosed related party transactions; (2) The DOJ’s investigation posed an existential risk to Clover as it derives most of its revenues from Medicare. (3) Clover’s sales were driven by an important undisclosed related party deal and misleading marketing to the elderly, not alleged “best-in-class” technology. (4) A significant portion of Clover sales came from an undisclosed relationship between Clover and a brokerage firm controlled by Clover’s sales director. and (5) as a result, defendants’ statements about their business, operations and prospects were materially false and misleading and / or were unfounded.

Clover Investors can attempt to become the Class Lead Prosecutor no later than April 6, 2021 through Kessler Topaz Meltzer & Check, LLP, or other attorney, or they can choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the dispute. To be named lead plaintiff, the court must determine that the class member’s claim is typical of the claims of other class members and that the class member is adequately representing the class. Your ability to get involved in a recovery will not be affected by whether or not you will be the lead plaintiff.

Kessler Topaz Meltzer & Check, LLP, pursues class actions in state and federal courts across the country involving securities fraud, fiduciary violations, and other federal and state law violations. Kessler Topaz Meltzer & Check, LLP, is a driving force behind corporate governance reform and has reclaimed billions of dollars on behalf of institutional and individual investors from the US and around the world. The company represents investors, consumers and whistleblowers (individuals who report fraudulent practices against the government and are involved in recovering government dollars). The complaint in this lawsuit was not filed by Kessler Topaz Meltzer & Check, LLP. Further information on Kessler Topaz Meltzer & Check, LLP can be found at www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro Jr., Esq.
Adrienne Bell, Esq.
280 Street of the King of Prussia
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

View source version on accesswire.com:
https://www.accesswire.com/632363/Kessler-Topaz-Meltzer-Check-LLP-Announces-Investor-Securities-Fraud-Class-Action-Lawsuit-Filed-Against-Clover-Health-Investments-Corp–CLOV

Comments are closed.